Your browser doesn't support javascript.
loading
A pilot study to troubleshoot quality control metrics when assessing circulating miRNA expression data reproducibility across study sites.
Permuth, Jennifer B; Mesa, Tania; Williams, Sion L; Cardentey, Yoslayma; Zhang, Dongyu; Pawlak, Erica A; Li, Jiannong; Cameron, Miles E; Ali, Karla N; Jeong, Daniel; Yoder, Sean J; Chen, Dung-Tsa; Trevino, Jose G; Merchant, Nipun; Malafa, Mokenge.
Afiliación
  • Permuth JB; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Mesa T; Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Williams SL; Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Cardentey Y; Oncogenomics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Zhang D; Oncogenomics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Pawlak EA; Department of Cancer Epidemiology, University of Florida, Gainesville, FL, USA.
  • Li J; GeoMx DSP, Nanostring Technologies, Seattle, WA, USA.
  • Cameron ME; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Ali KN; College of Medicine, University of Florida, Gainesville, FL, USA.
  • Jeong D; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Yoder SJ; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Chen DT; Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Tampa, FL, USA.
  • Trevino JG; Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Merchant N; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Malafa M; Department of Surgery, University of Florida, Gainesville, FL, USA.
Cancer Biomark ; 33(4): 467-478, 2022.
Article en En | MEDLINE | ID: mdl-35491771
ABSTRACT

BACKGROUND:

Given the growing interest in using microRNAs (miRNAs) as biomarkers of early disease, establishment of robust protocols and platforms for miRNA quantification in biological fluids is critical.

OBJECTIVE:

The goal of this multi-center pilot study was to evaluate the reproducibility of NanoString nCounter™ technology when analyzing the abundance of miRNAs in plasma and cystic fluid from patients with pancreatic lesions.

METHODS:

Using sample triplicates analyzed across three study sites, we assessed potential sources of variability (RNA isolation, sample processing/ligation, hybridization, and lot-to-lot variability) that may contribute to suboptimal reproducibility of miRNA abundance when using nCounter™, and evaluated expression of positive and negative controls, housekeeping genes, spike-in genes, and miRNAs.

RESULTS:

Positive controls showed a high correlation across samples from each site (median correlation coefficient, r> 0.9). Most negative control probes had expression levels below background. Housekeeping and spike-in genes each showed a similar distribution of expression and comparable pairwise correlation coefficients of replicate samples across sites. A total of 804 miRNAs showed a similar distribution of pairwise correlation coefficients between replicate samples (p= 0.93). After normalization and selecting miRNAs with expression levels above zero in 80% of samples, 55 miRNAs were identified; heatmap and principal component analysis revealed similar expression patterns and clustering in replicate samples.

CONCLUSIONS:

Findings from this pilot investigation suggest the nCounter platform can yield reproducible results across study sites. This study underscores the importance of implementing quality control procedures when designing multi-center evaluations of miRNA abundance.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: MicroARNs / MicroARN Circulante Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Biomark Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: MicroARNs / MicroARN Circulante Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Biomark Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos